Vimarsana
Biggest News Aggregation in the World

Page 37 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

Tabrecta Approved for Metastatic NSCLC on Confirmatory Data - Vimarsana News

Tabrecta Approved for Metastatic NSCLC on Confirmatory Data

The FDA has granted regular approval to Tabrecta (capmatinib) for the treatment of adults with metastatic NSCLC with MET exon 14 skipping.

Guardant Health Expands Use of Guardant Reveal Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers - Vimarsana News

Guardant Health Expands Use of Guardant Reveal Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers

15.08.2022 - Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Guardant Reveal, the only tissue-free test for the detection of residual and recurrent disease for colorectal cancer (CRC), is now available for patients ...

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC - Vimarsana News

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.

New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer - Vimarsana News

New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer

The FDA has approved Nubeqa (darolutamide) plus docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC - Vimarsana News

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.

Source: empr.com